About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1120 and TPST-1495, antagonists of PPARα and EP2/EP4, respectively. Both TPST-1120 and TPST-1495 are advancing through clinical trials designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1, a DNA repair enzyme that controls activation of the cGAS/
Investor Contact:
swheeler@wheelhouselsa.com
Media Contact:
Aljanae Reynolds
areynolds@tempesttx.com
__________________________
¹ If approved
Source: Tempest Therapeutics
2022 GlobeNewswire, Inc., source